Xultophy® (Insulin Degludec/Liraglutide) Safety and Effectiveness Evaluated in Korean T2DM Patients via rPMS
Background
Global prevalence of Type 2 diabetes mellitus (T2DM) continues to rise, necessitating effective and safe long-term management strategies to prevent micro- and macrovascular complications. While numerous antidiabetic agents are available, many patients require combination therapy to achieve optimal glycemic control due to the progressive nature of the disease. Fixed-ratio combinations, such as Xultophy® (insulin degludec/liraglutide), offer the convenience of combining basal insulin (insulin degludec) with a GLP-1 receptor agonist (liraglutide) in a single daily injection. Understanding the real-world safety and effectiveness of such combination therapies, particularly in diverse ethnic populations like Korea, is crucial to complement data from controlled clinical trials and inform evidence-based clinical practice.
Study Design
This multi-center, prospective, open-label, single-arm, non-interventional regulatory post-marketing surveillance (rPMS) study is being conducted in Korea. Its aim is to evaluate the safety and effectiveness of Xultophy® (insulin degludec/liraglutide) when initiated according to its label in adults diagnosed with type 2 diabetes mellitus (T2DM). Participants will receive Xultophy® as prescribed by their treating physician, reflecting routine clinical practice. The study duration is approximately 26 weeks, during which safety and effectiveness endpoints will be monitored.
Results
This abstract describes the comprehensive study protocol and its primary objectives; however, it does not present any empirical results or findings from the investigation itself. The study is meticulously designed to collect robust real-world data pertaining to the safety profile and the effectiveness in achieving glycemic control with Xultophy® in a routine clinical setting. Consequently, specific quantitative data, such as changes in HbA1c levels, body weight alterations, or detailed adverse event rates, are not yet available for reporting. Therefore, no statistical significance, confidence intervals, or specific clinical observations can be reported at this preliminary stage, as the study is either ongoing or its results are pending publication.
Why It Matters
This ongoing regulatory post-marketing surveillance study is crucial for gathering real-world evidence on Xultophy® (insulin degludec/liraglutide) in a Korean T2DM population. While randomized controlled trials establish efficacy and safety under highly controlled conditions, rPMS studies provide vital insights into how a drug performs in diverse patient cohorts, with varying comorbidities and concomitant medications, reflecting actual clinical practice. Understanding Xultophy®'s safety and effectiveness in routine use will help refine prescribing guidelines and inform healthcare providers about its practical utility and potential risks outside of trial settings. This data is essential for optimizing long-term diabetes management strategies and ensuring patient safety in broader clinical application.